Short Course Radical Cure of P. Vivax Malaria in Nepal

Summary

This study is designed as a multicentre randomized, open label trial to assess the safety and efficacy of a low dose short course PQ treatment (3.5mg/kg total dose given over 7 days) in glucose-6-phosphate dehydrogenase (G6PD) normal patients with P.vivax and P falciparum to reduce the risk of subsequent P.vivax episodes.

Timeline

Start

2021-10-27

Primary completion

2024-03-31

Completion

2024-03-31

Publications

• Ghimire P, Dahal G, Adhikari N, Rijal KR, Adhikari S, Banjara MR, Mnjala H, Lee G, Weston S, Rumaseb A, Rai A, Ley B, Hossain MS, Simpson JA, Rajasekhar M, Adhikari B, Price RN, Lal BK, Thriemer K. Short-Course Low-Dose Primaquine for Radical Cure in G6PD-Normal Patients in the Pre-Elimination Context of Nepal. Trop Med Int Health. 2026 Apr 25. doi: 10.1111/tmi.70145. Online ahead of print.

Drugs

Indications